Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463819 | 0.89 | HSD11B1 (0.38) | CYP11B1CYP11B2 | |
| Bromide SCHEMBL4466117 | 0.88 | HSD11B1 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL4483243 | 0.87 | CYP2A6 (0.41) | ALOX5APCYP11B1CYP11B2GSK3B | |
| SCHEMBL4475112 | 0.86 | CHRNA7 (0.37) | ALOX5APROCK1 | |
| SCHEMBL4470449 | 0.86 | SLC6A2 (0.38) | — | |
| SCHEMBL4475930 | 0.84 | HRH4 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL4463735 | 0.83 | RXFP1 (0.39) | CYP11B1 | |
| SCHEMBL4461401 | 0.83 | ALOX5AP (0.31) | ALOX5AP | |
| SCHEMBL5220760 | 0.83 | CYP11B1 (0.36) | ALOX5APCYP11B1CYP11B2 | |
| Bromide SCHEMBL4479130 | 0.82 | CYP11B1 (0.35) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585974-B2 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2009-09-08 | — | — | US | claimed |
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | claimed |
| EP-1465893-B1 | DERIVATIVES OF 5-(PYRIDIN-3-YL)-1-AZABICYCLO (3.2.1) OCTANE, THE PREPARATION THEREOF AND THE APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | PAICS, CYC1, AADAC | ALOX5AP 644/4885CYP11B1 136/4885CYP11B2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.